Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 372-378

  Grime, Ken ^a   Paine, Stuart W ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CEFALEXIN; CEFAMANDOLE; CEFAZOLIN; CEFIXIME; CEFOPERAZONE; CEFOTETAN; CEFPIRAMIDE; CEFTRIAXONE; CIPROFLOXACIN; DICLOFENAC; DIGOXIN; DOXORUBICIN; ERYTHROMYCIN; FEXOFENADINE; LATAMOXEF; METHADONE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NAPSAGATRAN; ORGANIC ANION TRANSPORTER; PRAVASTATIN; RANITIDINE; VALSARTAN; VINCRISTINE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; DOG; DRUG CLEARANCE; DRUG EXCRETION; DRUG TRANSPORT; DRUG UPTAKE; HEPATOBILIARY SYSTEM; HUMAN; LIVER CLEARANCE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BODY WEIGHT; DOGS; DRUG ADMINISTRATION ROUTES; HUMANS; LIVER; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RATS; SPECIES SPECIFICITY;

CANIS FAMILIARIS; RATTUS;

EID: 84872696088     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049312     Document Type: Article

References (94)

1. Abe K, Bridges AS, and Brouwer KL (2009) Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 37:447-452.
2. Arvidsson A, Alván G, Angelin B, Borgå O, and Nord CE (1982) Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother 10:207-215. (Pubitemid 13253889)
3. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, and Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8: 33-45. (Pubitemid 46043890)
4. Bi YA, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658-1665. (Pubitemid 44285409)
5. Bourdet DL, Pritchard JB, and Thakker DR (2005) Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 315:1288-1297. (Pubitemid 41635417)
6. Brogard JM, Audhuy B, Pinget M, and Dorner M (1984) [Evaluation of the biliary passage of beta-lactam antibiotics]. Ann Med Interne (Paris) 135:512-518. (Pubitemid 15197743)
7. Brogard JM, Jehl F, Adloff M, Blickle JF, and Monteil H (1988) High hepatic excretion in humans of cefpiramide, a new cephalosporin. Antimicrob Agents Chemother 32:1360-1364.
8. Brown CDA, Sayer R, Windass AS, Haslam IS, De Broe ME, D'Haese PC, and Verhulst A (2008) Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233:428-438.
9. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, and Mullins F (1997) Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 62:272-278. (Pubitemid 27417792)
10. Choi MK, Kim H, Han YH, Song IS, and Shim CK (2009) Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica 39: 171-181.
11. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and Pglycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871. (Pubitemid 29347585)
12. Fujiwara K, Shin M, and Miyazaki T (2011) A probable relationship between characteristic accumulation of doxorubicin and P-glycoprotein transporter in rat liver. J Mol Histol 42: 409-415.
13. Gardiner P and Paine SW (2011) The impact of hepatic uptake on the pharmacokinetics of organic anions. Drug Metab Dispos 39:1930-1938.
14. Goodman and Gilman (1990) The Pharmacological Basis of Therapeutics, 10th ed, McGraw Hill Publishers, New York.
15. Grime K and Riley RJ (2006) The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7: 251-264.
16. Grime K, Webborn PJ, and Riley RJ (2008) Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. Drug Metab Dispos 36:1670-1678.
17. Gui C, Obaidat A, Chaguturu R, and Hagenbuch B (2010) Development of a cell-based highthroughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1-8.
18. Hariharan S, Gunda S, Mishra GP, Pal D, and Mitra AK (2009) Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res 26:1270-1282.
19. Hatanaka T, Honda S, Sasaki S, Katayama K, and Koizumi T (1998) Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin. J Pharmacokinet Biopharm 26:329-347. (Pubitemid 29143568)
20. Hedman A, Angelin B, Arvidsson A, and Dahlqvist R (1991) No effect of probenecid on the renal and biliary clearances of digoxin in man. Br J Clin Pharmacol 32:63-67.
21. Hidemura K, Zhao YL, Ito K, Nakao A, Tatsumi Y, Kanazawa H, Takagi K, Ohta M, and Hasegawa T (2003) Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob Agents Chemother 47:1636-1642. (Pubitemid 36548548)
22. Hilmer SN, Cogger VC, Muller M, and Le Couteur DG (2004) The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos 32:794-799. (Pubitemid 38955607)
23. Huang SM, Tsai TR, Yeh PH, and Tsai TH (2005) Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. J Chromatogr A 1073:297-302.
24. Iguchi H, Tone H, Kiyosaki T, Ishikura T, Takeuchi T, and Umezawa H (1986) Pharmacokinetics and disposition of (2"R)-49-O- tetrahydropyranyladriamycin in dogs. Jpn J Antibiot 39: 638-652.
25. Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito K, Suzuki H, and Sugiyama Y (1999) Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 290:1324-1330. (Pubitemid 29400276)
26. Jackson DV, Jr., Castle MC, and Bender RA (1978) Biliary excretion of vincristine. Clin Pharmacol Ther 24:101-107. (Pubitemid 8407218)
27. Jaisue S, Gerber JP, and Davey AK (2010) Pharmacokinetics of fexofenadine following LPS administration to rats. Xenobiotica 40:743-750.
28. Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, and Tsuji A (2008) Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos 36:1088-1096. (Pubitemid 351717466)
29. Kemmerich B, Lode H, Borner K, Belmega D, Jendroschek T, Koeppe P, and Goertz G (1983) Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother 12:27-37. (Pubitemid 13069656)
30. Klotz U and Walker S (1990) Biliary excretion of H2-receptor antagonists. Eur J Clin Pharmacol 39:91-92.
31. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M, and Kuwano M (1997) A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57:5475-5479. (Pubitemid 28006750)
32. Kreek MJ, Kalisman M, Irwin M, Jaffery NF, and Scheflan M (1980) Biliary secretion of methadone and methadone metabolites in man. Res Commun Chem Pathol Pharmacol 29: 67-78. (Pubitemid 10082333)
33. Krishna R, McIntosh N, Riggs KW, and Mayer LD (1999) Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 5:2939-2947. (Pubitemid 29493973)
34. Kusuhara H and Sugiyama Y (2010) Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab Rev 42:539-550.
35. Lavé T, Chapman K, Goldsmith P, and Rowland M (2009) Human clearance prediction: shifting the paradigm. Expert Opin Drug Metab Toxicol 5:1039-1048.
36. Lam JL, Okochi H, Huang Y, and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporterenzyme interplay. Drug Metab Dispos 34:1336-1344. (Pubitemid 44079874)
37. LeCluyse EL, Audus KL, and Hochman JH (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266:C1764-C1774. (Pubitemid 24220826)
38. Li N, Zhang Y, Hua F, and Lai Y (2009) Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos 37:66-73.
39. Mahmood I (2005) Interspecies scaling of biliary excreted drugs: a comparison of several methods. J Pharm Sci 94:883-892. (Pubitemid 40577320)
40. Mahmood I and Sahajwalla C (2002) Interspecies scaling of biliary excreted drugs. J Pharm Sci 91:1908-1914. (Pubitemid 34810535)
41. Matsui H, Komiya M, Ikeda C, and Tachibana A (1984) Comparative pharmacokinetics of YM- 13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys. Antimicrob Agents Chemother 26:204-207. (Pubitemid 14050227)
42. Matsui H, Yano K, and Okuda T (1982) Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob Agents Chemother 22:213-217. (Pubitemid 12020109)
43. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, and Sugiyama Y (2008) Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483. (Pubitemid 351574837)
44. McEntee K, Clercx C, Pypendop B, Peeters D, Balligand M, D'Orio V, and Henroteaux M (1996) Cardiac performance in conscious healthy dogs during dobutamine infusion. Res Vet Sci 61: 234-239. (Pubitemid 126497071)
45. Miyazawa Y, Sato T, Kobayashi K, Akahori F, Suzuki T, and Miyashita H (1990) Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. Am J Vet Res 51: 605-610. (Pubitemid 20229924)
46. Mizojiri K, Norikura R, Takashima A, Tanaka H, Yoshimori T, Inazawa K, Yukawa T, Okabe H, and Sugeno K (1987) Disposition of moxalactam and N-methyltetrazolethiol in rats and monkeys. Antimicrob Agents Chemother 31:1169-1176. (Pubitemid 17157594)
47. Morris ME, Yang X, Gandhi YA, Bhansali SG, and Benincosa LJ (2012) Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. Biopharm Drug Dispos 33:1-14.
48. Muraoka I, Hasegawa T, Nadai M, Wang L, Haghgoo S, Tagaya O, and Nabeshima T (1995) Biliary and renal excretions of cefpiramide in Eisai hyperbilirubinemic rats. Antimicrob Agents Chemother 39:70-74.
49. Nakakariya M, Ono M, Amano N, Moriwaki T, Maeda K, and Sugiyama Y (2012) In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes. Drug Metab Dispos 40:602-609.
50. Nakakariya M, Shimada T, Irokawa M, Maeda T, and Tamai I (2008a) Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet 23:347-355.
51. Nakakariya M, Shimada T, Irokawa M, Koibuchi H, Iwanaga T, Yabuuchi H, Maeda T, and Tamai I (2008b) Predominant contribution of rat organic anion transporting polypeptide-2 (Oatp2) to hepatic uptake of beta-lactam antibiotics. Pharm Res 25:578-585. (Pubitemid 351357734)
52. Obach RS (2011) Predicting clearance in humans from in vitro data. Curr Top Med Chem 11: 334-339.
53. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405. (Pubitemid 351929323)
54. Paine SW, Ménochet K, Denton R, McGinnity DF, and Riley RJ (2011) Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos 39:1008-1013.
55. Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC, and Pla-Delfina JM (1991) Pharmacokinetics and bioavailability of diclofenac in the rat. J Pharmacokinet Biopharm 19:647-665.
56. Påhlman I, Edholm M, Kankaanranta S, and Odell M-L (1998) Pharmacokinetics of Susalimod, a highly biliary excreted sulphasalazine analogue, in various species. Non precictable human clearance by allometric scaling. Pharm Pharmacol Commun 4:493-498. (Pubitemid 28486739)
57. Ratzan KR, Baker HB, and Lauredo I (1978) Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile. Antimicrob Agents Chemother 13:985-987. (Pubitemid 8355005)
58. Rodriguez M, Ortega I, Soengas I, Suarez E, Lukas JC, and Calvo R (2004) Effect of Pglycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol 56:367-374. (Pubitemid 38380219)
59. Saikawa I, Takai A, Nakashima Y, Ikegami T, Hayakawa H, Takagi T, and Yamauchi H (1980) [Studies on the absorption distribution and excretion of 14C-labelled sodium 7-[D(-)-alpha-(4- ethyl-2,3-dioxo-1-piperazine-carboxamido)- alpha-(4-hydroxyphenyl l) acetamido]-3-[(1-methyl- 1H-tetrazol-5-yl) thiomethyl]-3-cephem-4-carboxylate (14C-cefoperazone) in rats and mice]. Jpn J Antibiot 33:1084-1096. (Pubitemid 11162198)
60. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, and Sugiyama Y (2004) Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 66:450-459. (Pubitemid 39329243)
61. Sawada Y, Hanano M, Sugiyama Y, and Iga T (1984) Prediction of the disposition of b-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm 12:241-261. (Pubitemid 14023152)
62. Scatina JA, Hicks DR, Kraml M, and Cayen MN (1989) Disposition of a new tetrahydrocarbazole analgesic drug in laboratory animals and man. Xenobiotica 19:991-1002. (Pubitemid 19230093)
63. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446. (Pubitemid 43363338)
64. Soars MG, Grime K, Sproston JL, Webborn PJ, and Riley RJ (2007) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859-865. (Pubitemid 46798596)
65. Sohlenius-Sternbeck A-K, Jones C, Ferguson D, Middleton BJ, Projean D, Floby E, Bylund J, and Afzelius L (2012) Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841-853.
66. Song S, Suzuki H, Kawai R, and Sugiyama Y (1999) Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27: 689-694. (Pubitemid 29252443)
67. Stierlin H and Faigle JW (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica 9:611-621. (Pubitemid 10167100)
68. Sun H, Huang Y, Frassetto L, and Benet LZ (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 32:1239-1246. (Pubitemid 39410907)
69. Sutfin TA, Gabrielsson M, and Regårdh CG (1987) Effects of biliary excretion on the disposition of felodipine and metabolites in the rat. Xenobiotica 17:1203-1214. (Pubitemid 17145849)
70. Swift B, Yue W, and Brouwer KL. (2010) 99mTechnetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes. Pharm Res 27:1987-1998.
71. Takimura Y and Lopez-Belio M (1955) Excretion of erythromycin through the biliary tract. Antibiotic Med Clin Ther 1:561-566.
72. Tahara H, Kusuhara H, Fuse E, and Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33:963-968. (Pubitemid 41002778)
73. Tanimura H, Tominaga S, Rai F, and Matsumoto H (1986) Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans. Arzneimittelforschung 36:1417-1420. (Pubitemid 16016265)
74. Taylor GL, Patel B, and Sullivan AT (2007) Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog. J Pharmacol Toxicol Methods 56:212-217. (Pubitemid 47375126)
75. Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, and Lee CA (2011) Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodiumdependent transporter expressed in HEK293 cells. Drug Metab Dispos 39:2093-2102.
76. Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, Terasaki T, Miyamoto E, Nightingale CH, and Yamana T (1983) Physiologically based pharmacokinetic model for betalactam antibiotics I: Tissue distribution and elimination in rats. J Pharm Sci 72:1239-1252. (Pubitemid 14229729)
77. Uchida K, Konishi M, Akiyoshi T, Igimi H, and Asakawa S (1985) Biliary excretion of latamoxef and N-methyltetrazolethiol in humans and rats. J Pharmacobiodyn 8:981-988. (Pubitemid 16175309)
78. van Zanden JJ, de Mul A, Wortelboer HM, Usta M, van Bladeren PJ, Rietjens IM, and Cnubben NH (2005) Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem Pharmacol 69:1657-1665. (Pubitemid 40719501)
79. Varma MV, Chang G, Lai Y, Feng B, El-Kattan AF, Litchfield J, and Goosen TC (2012) Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab Dispos 40:1527-1537.
80. Wang Z, Hamman MA, Huang S-M, Lesko LJ, and Hall SD (2002) Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71:414-420. (Pubitemid 34701348)
81. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
82. Watanabe T, Suzuki H, Sawada Y, Naito M, Tsuruo T, Inaba M, Hanano M, and Sugiyama Y (1995) Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J Hepatol 23:440-448.
83. Westphal JF, Jehl F, Schloegel M, Monteil H, and Brogard JM (1993) Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. Antimicrob Agents Chemother 37:1488-1491. (Pubitemid 23202377)
84. Wilby AJ, Maeda K, Courtney PF, Debori Y, Webborn PJ, Kitamura Y, Kusuhara H, Riley RJ, and Sugiyama Y (2011) Hepatic uptake in the dog: comparison of uptake in hepatocytes and human embryonic kidney cells expressing dog organic anion-transporting polypeptide 1B4. Drug Metab Dispos 39:2361-2369.
85. Wilkinson PM, Israel M, Pegg WJ, and Frei E, 3rd (1979) Comparative metabolism and excretion of adriamycin in man, monkey, and rat. Cancer Chemother Pharmacol 2:121-125. (Pubitemid 9221323)
86. Wright WE and Line VD (1980) Biliary excretion of cephalosporins in rats: influence of molecular weight. Antimicrob Agents Chemother 17:842-846. (Pubitemid 10112535)
87. Wyman JB, Bartholomew LG, Karlson AG, Wakim KG, and Cain JC (1968) Pancreatic, hepatic, and renal excretion of antibiotics in dogs. Observations on erythromycin, lincomycin, kanamycin, and colistimethate excretion. Arch Surg 97:46-50.
88. Yabe Y, Galetin A, and Houston JB (2011) Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808-1814.
89. Yamaguchi H, Takeuchi T, Okada M, Kobayashi M, Unno M, Abe T, Goto J, Hishinuma T, Shimada M, and Mano N (2011) Screening of antibiotics that interact with organic aniontransporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull 34:389-395.
90. Yamaguchi H, Yano I, Saito H, and Inui K (2004) Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res 21:330-338. (Pubitemid 38221980)
91. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, and Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247-1254.
92. Yamazaki M, Tokui T, Ishigami M, and Sugiyama Y (1996) Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos 17:775-789. (Pubitemid 26401289)
93. Yasui H, Yamaoka K, and Nakagawa T (1994) Alternative continuous infusion method for analysis of enterohepatic circulation and biliary excretion of cefixime in the rat. J Pharm Sci 83:819-823. (Pubitemid 24233757)
94. Yoshikawa N, Tsuji Y, Sato Y, Ikeda Y, Shinada Y, Kawanishi N, Tamaki A, and Kasai Y (1979) [Experimental study of the biliary excretion of antibiotic (cefotiam) in the presence of biliary tract obstruction (author's transl)]. Jpn J Antibiot 32:1101-1106. (Pubitemid 10073827)